Biomol Ther.  2020 Jul;28(4):293-301. 10.4062/biomolther.2020.002.

Recent Advances in the Development of Novel Drug Candidates for Regulating the Secretion of Pulmonary Mucus

Affiliations
  • 1Department of Pharmacology, School of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea
  • 2Smith Liberal Arts College and Department of Addiction Science, Graduate School, Sahmyook University, Seoul 01795, Republic of Korea

Abstract

Hypersecretion of pulmonary mucus is a major pathophysiological feature in allergic and inflammatory respiratory diseases including asthma and chronic obstructive pulmonary disease (COPD). Overproduction and/or oversecretion of mucus cause the airway obstruction and the colonization of pathogenic microbes. Developing a novel pharmacological agent to regulate the production and/or secretion of pulmonary mucus can be a useful strategy for the effective management of pathologic hypersecretion of mucus observed in COPD and asthma. Thus, in the present review, we tried to give an overview of the conventional pharmacotherapy for mucus-hypersecretory diseases and recent research results on searching for the novel candidate agents for controlling of pulmonary mucus hypersecretion, aiming to shed light on the potential efficacious pharmacotherapy of mucus-hypersecretory diseases.

Keyword

Mucus; Mucin; Hypersecretion; Pharmacotherapy
Full Text Links
  • BT
Share
  • Twitter
  • Facebook
Copyright © 2020 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr